MRVI · NASDAQ
Maravai LifeSciences Holdings, Inc.
$7.84 +0.26 (+3.62%)
Company overview
Maravai LifeSciences Holdings, Inc. is a life sciences company that provides products enabling the development of drug therapies, diagnostics, novel vaccines, and research on human diseases in the United States and internationally. The company's products address key phases of biopharmaceutical development, including nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during biopharmaceutical production, and products to detect protein expression in tissues of various species. The company operates in two segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents for the chemical synthesis, modification, labeling, and purification of DNA and RNA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.2B
- Employees
- 570
- Headquarters
- San Diego, CA
- Website
- maravai.com
- CEO
- Bernd Brust
- Listed
- November 20, 2020
- P/E
- -10.81
- Dividend yield
- 0.00%
Company financials
- Revenue
- $205M
- Gross profit
- $59.4M
- Operating income
- $44.9M
- EBITDA
- -$101M
- Net income
- -$105M
- EPS
- -$0.73
- Total assets
- $713M
- Total debt
- $35.3M
- Gross margin
- 29.00%
- Net margin
- -51.07%
- Earnings yield
- -9.25%
Showing FY 2025
MRVI
1D
NASDAQ
O7.73H7.89L7.28C7.74+0.29 (+3.89%)Vol3.19M
News